# Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

> **NCT01093222** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Extrahepatic Bile Duct Adenocarcinoma
- Gallbladder Adenocarcinoma
- Gallbladder Adenocarcinoma With Squamous Metaplasia
- Hilar Cholangiocarcinoma
- Recurrent Extrahepatic Bile Duct Carcinoma
- Recurrent Gallbladder Carcinoma
- Undifferentiated Gallbladder Carcinoma
- Unresectable Extrahepatic Bile Duct Carcinoma
- Unresectable Gallbladder Carcinoma

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT01093222
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-09
- **Final completion:** 2014-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093222, "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01093222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*